Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1

Status

Active not recruiting 15Completed 6Terminated 3Recruiting 3Not yet recruiting 3Withdrawn 1Available 1

Sponsor Class

OTHER 6INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 3

Interventions

pembrolizumab 184Carboplatin 130Paclitaxel 123Gemcitabine 122Docetaxel 96Cyclophosphamide 89Nivolumab 88Cisplatin 87Rituximab 71Dexamethasone 68Pemetrexed 64Bevacizumab 64Capecitabine 60atezolizumab 54fludarabine 49Azacitidine 49Fluorouracil 48130-nm albumin-bound paclitaxel 43venetoclax 41Trastuzumab 41Irinotecan 41Cetuximab 40Leucovorin 36Ipilimumab 36Erlotinib Hydrochloride 34Fulvestrant 32Cytarabine 32avelumab 31Oxaliplatin 31Albumin-Bound Paclitaxel 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × belantamab mafodotin × Clear all
NCT06655818 2025-03-03

Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM

GlaxoSmithKline

Phase 1/2 Terminated
4 enrolled 16 charts
Plasma cell

Multiple Myeloma

NCT06160609 2024-03-12

Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM

GlaxoSmithKline

Phase 1/2 Terminated
9 enrolled 14 charts
Plasma cell

Multiple Myeloma

NCT04549363 2023-12-13

Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab Mafodotin

GlaxoSmithKline

Phase 3 Terminated
16 enrolled 7 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡